Zevra Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for rare diseases with limited treatment options. The company markets two FDA-approved products: MIPLYFFA (arimoclomol) for neurological manifestations of Niemann-Pick disease type C, and OLPRUVA (sodium phenylbutyrate oral suspension) for certain urea cycle disorders, primarily through specialty pharmacy distribution in the United States. Revenue is generated from direct product sales, expanded access programs in select territories, royalties and milestone payments from license agreements, and consulting arrangements, while the company maintains a pipeline of clinical-stage candidates and pursues strategic acquisitions to expand its rare disease portfolio.